Datavault AI announced a binding term sheet with Wellgistics Health to form DelivMeds AI, Inc., a new healthcare-focused company expected to integrate blockchain-enabled healthcare infrastructure, AI-powered pharmacy services, biometric verification technologies, drone logistics intellectual property, and consumer health platforms. The combined transaction package carries an expected approximate asset value of $4 billion, subject to an independent fairness opinion.
The agreement between Datavault AI and Wellgistics Health expands the existing PharmacyChain™ license to include Healthcare-as-a-Service intellectual property while connecting DelivMeds AI to Wellgistics’ network of more than 6,500 pharmacies and over 200 manufacturers.
As part of the transaction structure, DelivMeds AI will also acquire the QOLPOM patent portfolio from EOS Technology Holdings and Scilex Holding Company, adding biometric pharmacodynamic verification technology and AI-enabled drone logistics capabilities designed for pharmaceutical delivery and diagnostic sample collection.
In addition, DelivMeds AI plans to acquire a controlling stake in Tollo Health, which develops medical foods and dietary supplements targeting GLP-1-related muscle loss, acute viral infections, and chronic viral conditions, including Long COVID. Tollo Health also brings its AI-powered consumer engagement application “Health Lives Here” and a marketing partnership with NFL Alumni Health.
Gerald Commissiong has concurrently been appointed Interim Co-CEO of Wellgistics Health as the companies work toward integrating the businesses into DelivMeds AI.
Commissiong said the combined business is intended to improve patient outcomes by integrating pharmaceutical-adjunct nutraceutical solutions with AI-personalized behavioral health technology and patient engagement workflows.
DelivMeds AI also plans to scale the “Health Lives Here” initiative nationally through the Wellgistics Pharmacy Network. The first pilot rollout is targeted for North Carolina beginning in July 2026 ahead of an official launch tied to NFL Alumni Health activities surrounding the 2026 Pro Football Hall of Fame Game in August.
Nathaniel T. Bradley, CEO of Datavault AI, said the company has been building infrastructure around blockchain-enabled pharmacy delivery, AI-driven logistics, and biometric verification technologies that can now be integrated into a direct-to-consumer healthcare platform.
Under the expanded PharmacyChain™ licensing arrangement, Wellgistics’ EinsteinRx™ AI platform will manage eligibility verification, onboarding, adherence support, prior authorization, and cash-pay prescription fulfillment. PharmacyChain™ will provide blockchain-enabled smart contract infrastructure supporting prescription drug dispensing workflows.
The QOLPOM intellectual property portfolio is designed to enable biometric verification of pharmacodynamic drug effects through wearable technologies and contactless identity verification for patient-specific medication deliveries. The platform also includes Data Driven Drones™ capabilities for delivery of medical supplies, biopharmaceutical drugs, and diagnostic sample collection kits, particularly targeting rural and underserved communities.
Tollo Health’s portfolio adds telemedicine, AI-enabled coaching, and compliance management tools alongside products designed to address muscle loss associated with GLP-1 therapies, Long COVID, and acute viral infections. The company’s planned launch of Forzet™ as a medical food targeting muscle loss associated with weight-loss therapies was recently featured with NFL Alumni Health during the 2026 NFL Draft in Pittsburgh.
The transactions remain subject to due diligence, financing arrangements, fairness opinions, board approvals, execution of definitive agreements, and customary closing conditions.
KEY QUOTES:
“There is a tremendous opportunity to transition this highly valuable portfolio of assets into a robust business centered on quantifying and improving patient outcomes using DelivMeds’ unique access to a proprietary healthcare data stack. By combining proprietary pharmaceutical-adjunct nutraceutical solutions with AI-personalized behavioral health technology into patient engagement workflows, we have a unique approach to drive digital health adoption and improve compliance.”
Gerald Commissiong, Interim Co-CEO, Wellgistics Health
“DelivMeds AI brings together the infrastructure we have been building – blockchain-enabled pharmacy delivery, AI-driven logistics, and biometric verification – into a single direct-to-consumer platform that serves patients where they live. This is data infrastructure meeting real-world healthcare delivery at scale.”
Nathaniel T. Bradley, CEO, Datavault AI
